Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MGTX NASDAQ:PHAR NASDAQ:SDGR NASDAQ:SLRN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMGTXMeiraGTx$9.24-2.6%$9.07$4.82▼$11.85$855.72M1.23703,700 shs383,928 shsPHARPharming Group$12.60-1.6%$15.57$9.54▼$21.34$889.88M0.0413,348 shs25,525 shsSDGRSchrodinger$13.30+0.5%$12.09$10.94▼$27.63$981.87M1.571.41 million shs1.32 million shsSLRNAcelyrin$2.27$2.27$1.95▼$2.66$229.17M1.071.09 million shsN/A7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMGTXMeiraGTx-2.63%-1.70%-7.88%+24.03%+74.34%PHARPharming Group-1.64%-2.48%-25.29%-22.98%+20.11%SDGRSchrodinger+0.53%+11.30%+7.69%+15.35%-35.15%SLRNAcelyrin0.00%0.00%0.00%0.00%-0.35%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMGTXMeiraGTx$9.24-2.6%$9.07$4.82▼$11.85$855.72M1.23703,700 shs383,928 shsPHARPharming Group$12.60-1.6%$15.57$9.54▼$21.34$889.88M0.0413,348 shs25,525 shsSDGRSchrodinger$13.30+0.5%$12.09$10.94▼$27.63$981.87M1.571.41 million shs1.32 million shsSLRNAcelyrin$2.27$2.27$1.95▼$2.66$229.17M1.071.09 million shsN/A7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMGTXMeiraGTx-2.63%-1.70%-7.88%+24.03%+74.34%PHARPharming Group-1.64%-2.48%-25.29%-22.98%+20.11%SDGRSchrodinger+0.53%+11.30%+7.69%+15.35%-35.15%SLRNAcelyrin0.00%0.00%0.00%0.00%-0.35%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMGTXMeiraGTx 2.75Moderate Buy$25.83179.58% UpsidePHARPharming Group 2.40Hold$38.33204.23% UpsideSDGRSchrodinger 2.33Hold$20.2552.26% UpsideSLRNAcelyrin 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SLRN, SDGR, PHAR, and MGTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2026MGTXMeiraGTx Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$24.00 ➝ $25.005/14/2026SDGRSchrodinger Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$19.00 ➝ $17.005/11/2026PHARPharming Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D)4/27/2026PHARPharming Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)4/22/2026MGTXMeiraGTx Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$26.00 ➝ $30.004/21/2026MGTXMeiraGTx Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/17/2026MGTXMeiraGTx Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$16.00 ➝ $24.004/13/2026PHARPharming Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)4/10/2026PHARPharming Group Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold4/10/2026PHARPharming Group Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$37.004/8/2026SDGRSchrodinger KeyCorpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$25.00 ➝ $20.00(Data available from 5/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMGTXMeiraGTx$81.39M10.51N/AN/A($0.63) per share-14.67PHARPharming Group$376.13M2.37$0.20 per share62.83$3.81 per share3.31SDGRSchrodinger$255.87M3.84N/AN/A$4.25 per share3.13SLRNAcelyrinN/AN/AN/AN/A$6.74 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMGTXMeiraGTx-$114.20M-$1.48N/AN/AN/A-151.12%-1,065.47%-54.96%N/APHARPharming Group$2.85M$0.1678.7519.38N/A3.30%4.64%2.55%7/30/2026 (Estimated)SDGRSchrodinger-$103.26M-$1.41N/AN/AN/A-40.61%-30.85%-15.32%8/5/2026 (Estimated)SLRNAcelyrin-$381.64M-$2.69N/AN/AN/AN/A-44.12%-39.02%N/ALatest SLRN, SDGR, PHAR, and MGTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026MGTXMeiraGTx-$0.6060-$0.57+$0.0360-$0.57$17.00 million$0.29 million5/7/2026Q1 2026PHARPharming Group$0.05-$0.07-$0.12-$0.07$92.06 million$72.45 million5/5/2026Q1 2026SDGRSchrodinger-$0.56-$0.81-$0.25-$0.81$47.57 million$58.59 million3/26/2026Q4 2025MGTXMeiraGTx-$0.60$0.19+$0.79$0.19$3.87 million$75.36 million3/12/2026Q4 2025PHARPharming Group$0.15$0.07-$0.08$0.07$111.76 million$106.50 million2/25/2026Q4 2025SDGRSchrodinger-$0.13$0.44+$0.57$0.44$83.66 million$87.24 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthMGTXMeiraGTxN/AN/AN/AN/AN/APHARPharming GroupN/AN/AN/AN/AN/ASDGRSchrodingerN/AN/AN/AN/AN/ASLRNAcelyrinN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMGTXMeiraGTxN/A0.550.55PHARPharming Group0.352.632.06SDGRSchrodingerN/A2.742.74SLRNAcelyrinN/A7.157.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMGTXMeiraGTx67.48%PHARPharming Group0.03%SDGRSchrodinger79.05%SLRNAcelyrin87.31%Insider OwnershipCompanyInsider OwnershipMGTXMeiraGTx7.50%PHARPharming Group2.07%SDGRSchrodinger10.10%SLRNAcelyrin13.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMGTXMeiraGTx30092.61 million85.66 millionOptionablePHARPharming Group28070.62 million69.16 millionNot OptionableSDGRSchrodinger79073.82 million66.37 millionOptionableSLRNAcelyrin135100.95 million86.68 millionNo DataSLRN, SDGR, PHAR, and MGTX HeadlinesRecent News About These CompaniesACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated DiseasesMay 13, 2025 | globenewswire.comLeading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with AlumisMay 6, 2025 | globenewswire.comAcelyrin urges stockholders to vote for proposed merger with AlumisMay 2, 2025 | finance.yahoo.comACELYRIN Reiterates Benefits of Value-Maximizing Combination with AlumisMay 1, 2025 | globenewswire.comAlumis and ACELYRIN Announce Amended Merger AgreementApril 21, 2025 | globenewswire.comACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRNApril 16, 2025 | businesswire.comAlumis Inc.; ACELYRIN, INC.: Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed MergerApril 5, 2025 | finanznachrichten.deAlumis Inc. and ACELYRIN, INC. File Joint Definitive Proxy Statement for Proposed MergerApril 5, 2025 | finanznachrichten.deSTOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating The Merger - SLRN, TURN, BHLB, MHLDMarch 30, 2025 | morningstar.comMInsider Selling: Acelyrin, Inc. (NASDAQ:SLRN) Insider Sells 3,913 Shares of StockMarch 20, 2025 | insidertrades.comAcelyrin, Inc. (SLRN): One of the Best Short-Term Stocks to Buy Right NowMarch 18, 2025 | msn.comACELYRIN Adopts Limited-Duration Stockholder Rights PlanMarch 13, 2025 | globenewswire.comAcelyrin: Potential Buyout Led By Concentra BiosciencesMarch 12, 2025 | seekingalpha.comIs Acelyrin, Inc. (SLRN) the Best Micro Cap Stock to Buy Now?March 7, 2025 | insidermonkey.comACELYRIN, INC.: ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed MergerMarch 4, 2025 | finanznachrichten.deAcelyrin says Concentra indication not expected to result in superior proposalMarch 4, 2025 | markets.businessinsider.comAcelyrin falls as Acelyrin reaffirms deal commitmentMarch 4, 2025 | msn.comAcelyrin, Alumis reaffirm strategic, financial rationale of proposed mergerMarch 4, 2025 | markets.businessinsider.comACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed MergerMarch 4, 2025 | globenewswire.comACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis MergerMarch 4, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Healthcare Stocks Set to Benefit From the One Big Beautiful BillBy Chris Markoch | May 10, 2026The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the BeatBy Jessica Mitacek | May 2, 2026Hims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?By Jessica Mitacek | May 12, 20262 Ways to Play the Big Pharma Patent CliffBy Nathan Reiff | May 15, 2026The Silver Lining of Last Week's Hims & Hers Earnings MissBy Jessica Mitacek | May 21, 2026SLRN, SDGR, PHAR, and MGTX Company DescriptionsMeiraGTx NASDAQ:MGTX$9.24 -0.25 (-2.63%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$9.25 +0.01 (+0.11%) As of 05/22/2026 05:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.Pharming Group NASDAQ:PHAR$12.60 -0.21 (-1.64%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$13.03 +0.43 (+3.38%) As of 05/22/2026 06:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.Schrodinger NASDAQ:SDGR$13.30 +0.07 (+0.53%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$13.42 +0.12 (+0.92%) As of 05/22/2026 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.Acelyrin NASDAQ:SLRNAcelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
